Patents by Inventor Raymond John Owens
Raymond John Owens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030148406Abstract: A multivalent antigen-binding protein comprises a first Fv fragment bound to at least one further Fv fragment by a connecting structure which links the Fv fragments to each other but which maintains them spaced apart such that the proteins are capable of binding to adjacent antigenic determinants. Typically the connecting structure comprises a spacing polypeptide sequence, which may be about 3 to 16 amino acids in length, connected to a linkage unit which may be a synthetic chemical linker, e.g., a maleimide linker, or is a polypeptide sequence leading from the spacing sequence. In a particularly preferred embodiment, the multivalent antigen binding protein comprises a VH domain having attached to its C-terminal end a V-C joining sequence and an antibody hinge sequence. Preferably one or more of the Fv fragments is a single chain Fv (scFv). The proteins are preferably prepared by recombinant DNA techniques and are useful for in vivo therapeutic and especially diagnostic applications.Type: ApplicationFiled: January 7, 1999Publication date: August 7, 2003Inventors: DAVID JOHN KING, ANDREW MOUNTAIN, RAYMOND JOHN OWENS, GEOFFREY THOMAS YARRANTON
-
Patent number: 6506881Abstract: Humanized antibody molecules (HAMs) are described having specificity for human milk fat globule and having an antigen binding site wherein at least one of the complementarity determining regions (CDRs) of the variable domains is derived from the mouse monoclonal antibody CTMO1 and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin. The HAMs may be chimeric humanized antibodies or CDR-grafted humanized antibodies and are preferably produced by recombinant DNA techniques. The HAMs are useful for in vivo diagnosis and therapy.Type: GrantFiled: May 25, 1995Date of Patent: January 14, 2003Assignee: Celltech R&D LimitedInventors: John Robert Adair, Raymond John Owens, Terence Seward Baker, Alan Howard Lyons
-
Patent number: 6407214Abstract: This invention relates to whole antibodies of neutral isotype having specificity for E-selection, process for their preparation (using vectors), pharmaceutical compositions containing them, and their use in therapy (e.g. for inflammatory disorders) and diagnosis. Said antibodies are variants of natural antibodies altered in the Fc region, especially in the CH2 domain, so that the interactions with antibodies Fc receptors and complement are absent or very low.Type: GrantFiled: June 5, 2000Date of Patent: June 18, 2002Assignee: Celltech Therapeutics LimitedInventors: Raymond John Owens, Martyn Kim Robinson
-
Patent number: 6307026Abstract: A33 antigen binding proteins are described for use in the diagnosis or treatment of colorectal tumors and metastases arising therefrom. The binding protein may be a humanized A33 antibody, including complete antibody molecules, fragments thereof, and particularly, multivalent monospecific proteins comprising two, three, four or more antibodies or fragments thereof, bound to each other by a cross-linking agent. For diagnosis or therapy, the humanized A33 antibody may be linked to a reporter or effector molecule.Type: GrantFiled: November 21, 1997Date of Patent: October 23, 2001Assignee: Celltech LimitedInventors: David John King, John Robert Adair, Raymond John Owens
-
Patent number: 6291199Abstract: Recombinant human phosphodiesterase type IVC is described, and DNA coding for it. Particular conformers of the enzyme are identified, including a R- and S-rolipram stereoselective conformer which is obtainable by expression of human phosphodiesterase type IVC DNA in mammalian or insect cells. The recombinant enzyme may be used in a screen to select a compound capable of modulating the action of the enzyme, or as an immunogen to generate an antibody.Type: GrantFiled: May 15, 1998Date of Patent: September 18, 2001Assignee: Celltech Therapeutics LimitedInventors: Raymond John Owens, Martin John Perry, Simon Mark Lumb
-
Patent number: 6204007Abstract: This invention relates to whole antibodies of neutral isotype having specificity for E-selectin, process for their preparation (using vectors), pharmaceutical compositions containing them, and their use in therapy and diagnosis. Said antibodies are variants of natural antibodies altered in the Fc region, especially in the CH2 domain, so that the interactions with antibodies Fc receptors and complement are very low.Type: GrantFiled: November 25, 1996Date of Patent: March 20, 2001Assignee: Celltech Therapeutics LimitedInventors: Raymond John Owens, Martyn Kim Robinson
-
Patent number: 5965405Abstract: Methods for preparing Fv fragments which lack linking polypeptides in eukaryotic cells are provided.Type: GrantFiled: December 13, 1993Date of Patent: October 12, 1999Assignee: Celltech LimitedInventors: Gregory Paul Winter, Lutz Riechmann, Geoffrey Thomas Yarranton, Mark William Bodmer, Raymond John Owens
-
Patent number: 5877293Abstract: The present invention provides humanized antibody molecules (HAMs) having specificity for carcinoembryonic antigen (CEA) and having an antigen binding site wherein at least one of the complementarity determining regions (CDRs) of the variable domains is derived from the mouse monoclonal antibody A5B7 (A5B7 MAB) and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin. The HAMs may be chimeric humanized antibodies or CDR-grafted humanized antibodies and are preferably produced by recombinant DNA techniques. The HAMs are useful for in vivo diagnosis and therapy.Type: GrantFiled: May 24, 1995Date of Patent: March 2, 1999Assignee: Celltech Therapeutics LimitedInventors: John Robert Adair, Mark William Bodmer, Andrew Mountain, Raymond John Owens
-
Patent number: 5864019Abstract: A multivalent antigen-binding protein comprises a first Fv fragment bound to at least one further Fv fragment by a connecting structure which links the Fv fragments to each other but which maintains them spaced apart such that the proteins are capable of binding to adjacent antigenic determinants. Typically the connecting structure comprises a spacing polypeptide sequence, which may be about 3 to 16 amino acids in length, connected to a linkage unit which may be a synthetic chemical linker, e.g., a maleimide linker, or is a polypeptide sequence leading from the spacing sequence. In a particularly preferred embodiment, the multivalent antigen binding protein comprises a VH domain having attached to its C-terminal end a V-C joining sequence and an antibody hinge sequence. Preferably one or more of the Fv fragments is a single chain Fv (scFv). The proteins are preferably prepared by recombinant DNA techniques and are useful for in vivo therapeutic and especially diagnostic applications.Type: GrantFiled: March 6, 1995Date of Patent: January 26, 1999Assignee: Celltech LimitedInventors: David John King, Andrew Mountain, Raymond John Owens, Geoffrey Thomas Yarranton
-
Patent number: 5851784Abstract: Recombinant human phosphodiesterase type IVC is described, and DNA coding for it. Particular conformers of the enzyme are identified, including a R- and S-rolipram stereoselective conformer which is obtainable by expression of human phosphodiesterase type IVC DNA in mammalian or insect cells. The recombinant enzyme may be used in a screen to select a compound capable of modulating the action of the enzyme, or as an immunogen to generate an antibody.Type: GrantFiled: December 22, 1995Date of Patent: December 22, 1998Assignee: Celltech Therapeutics, LimitedInventors: Raymond John Owens, Martin John Perry, Simon Mark Lumb